Rankings
▼
Calendar
RAPP
Rapport Therapeutics, Inc. Common Stock
$1B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$15,000
Operating Income
-$5M
Net Income
-$6M
EPS (Diluted)
$-0.03
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$723,000
← FY 2023
All Quarters
Q2 2023 →
RAPP Q1 2023 Earnings — Rapport Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
